Long-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis

Fernández, O. ; Arroyo, R. ; Martínez-Yélamos, S. ; Marco, M. ; Merino, J.A.G. ; Muñoz, D. ; Merino, E. ; Roque, A. ; Munoz, C. ; Foronda, J. ; Sanchis, G. ; Barrero, F. ; Ara, J.R. ; Oliva, P. ; Menéndez, M.A. ; Solar, D.M. ; Oterino, A. ; Brieva, L. ; Escartín, A. ; Ramió, L. ; Martín, G. ; Blanco, Y. ; García, R. ; Ayuso, T. ; Olascoaga, J. ; Rodríguez-Antigüedad, A. ; Coret, F. ; Belenguer, A. ; Cervelló, Á. ; Pérez, N. ; López, A. ; Castro, M.D. ; Meca, V. ; Borrega, L. ; Puerta, I.

Resumen: The effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart® electronic device provides useful information about adherence to the treatment with subcutaneous (sc) interferon (IFN) ß-1a (Rebif®). The aim of the study was to determine long-term adherence to this treatment in patients with relapsing- remitting multiple sclerosis (RRMS). This retrospective multicentre observational study analysed 258 patients with RRMS who were receiving sc IFN ß-1a (Rebif®) treatment by using RebiSmart® until replacement (36 months maximum lifetime) or treatment discontinuation. Adherence was calculated with data (injection dosage, time, and date) automatically recorded by RebiSmart®. Patients in the study had a mean age of 41 years with a female proportion of 68%. Mean EDSS score at start of treatment was 1.8 (95% CI, 1.6-1.9). Overall adherence was 92.6%(95% CI, 90.6-94.5%). A total of 30.2% of patients achieved an adherence rate of 100%, 80.6% at least 90%, and only 13.2% of patients showed a suboptimal adherence (<80%). A total of 59.9% of subjects were relapse-free after treatment initiation. Among 106 subjects (41.1%) who experienced, on average, 1.4 relapses, the majority were mild (40.6%) or moderate (47.2%). Having experienced relapses from the beginning of the treatment was the only variable significantly related to achieving an adherence of at least 80% (OR = 3.06, 1.28-7.31). Results of this study indicate that sc IFN ß-1a administration facilitated by RebiSmart® could lead to high rates of adherence to a prescribed dose regimen over 36 months.

Idioma: Inglés

DOI: 10.1371/journal.pone.0160313

Año: 2016

Publicado en: PloS one 11, 8 (2016), 0160313 [12p.]
ISSN: 1932-6203

Factor impacto JCR: 2.806 (2016)

Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 15 / 63 = 0.238 (2016) - Q1 - T1

Factor impacto SCIMAGO: 1.236 - Agricultural and Biological Sciences (miscellaneous) (Q1) - Medicine (miscellaneous) (Q1) - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Tipo y forma: Article (Published version)